Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Aug 25.

Published in final edited form as: Eur Urol. 2012 Jan 5;61(4):826–833. doi: 10.1016/j.eururo.2011.12.057

Table 4.

Incidence of grades 3 and 4 adverse events in elderly patients and the total study population^*

	Age ≥65 yr		Age ≥70 yr		All patients

	Everolimus plus BSC (n = 111)	Placebo plus BSC (n = 39)	Everolimus plus BSC (n = 52)	Placebo plus BSC (n = 20)	Everolimus plus BSC (n = 274)	Placebo plus BSC (n = 137)
Adverse event, %
Anemia	14	3	12	0	10	5
Infection	11	3	12	0	10	1
Lymphopenia	9	0	10	0	4	0
Hyperglycemia	8	3	8	5	6	2
Stomatitis	6	0	4	0	4	0
Fatigue	3	3	6	0	5	3

BSC = best supportive care.

^*

Adverse events with combined grades 3 and 4 incidence of >5% in the everolimus arm of either elderly subpopulation are shown.